Piombino Dese, Italy-based Stevanato Group designed Vertiva with the ability to switch between basal and bolus injections. It has suitability for a wide range of subcutaneous therapies.
In March, Stevanato Group announced plans to bring this on-body device to market through a collaboration with Thermo Fisher Scientific. The companies plan to offer the platform as an integrated device and fill-and-finish solution.
The company designed Vertiva with a single-use pod featuring a pre-filled and pre-loaded 3mL ISO cartridge. It also comes with a multi-use controller for potential sustainability and affordability benefits. Both parts communicate through a patented, magnetically coupled drive mechanism.
Stevanato Group said its device can adapt to different delivery profiles and enable the administration of small-molecule drugs and biologics. The company has the design under development to cover a broad range of volumes up to 10mL.
Get the full story at our sister site, Drug Delivery Business News.